2015
DOI: 10.1016/j.drudis.2015.01.005
|View full text |Cite
|
Sign up to set email alerts
|

Preclinical and clinical evidence for stem cell therapies as treatment for diabetic wounds

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
24
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 37 publications
(25 citation statements)
references
References 135 publications
1
24
0
Order By: Relevance
“…The ASCs significantly improved wound healing outcomes by day 16 compared to the controls. Stem cell therapies delivered in biomaterials have also shown promise for burn wound healing (Ozturk and Karagoz, 2015), diabetic ulcers (Heublein et al, 2015), and cutaneous wound healing (Branski et al, 2009). Microporous annealed particle (MAP) gels were created by mixing pre-gel mixture including a PEG-VS containing an RGD peptide region and matrix metalloproteinase (MMP) substrate with MMP crosslinker solution in a microfluidic channel to make gels that were annealed using FXIIIa into a final microporous scaffold (Griffin et al, 2015).…”
Section: Biomaterial-based Wound Therapiesmentioning
confidence: 99%
See 1 more Smart Citation
“…The ASCs significantly improved wound healing outcomes by day 16 compared to the controls. Stem cell therapies delivered in biomaterials have also shown promise for burn wound healing (Ozturk and Karagoz, 2015), diabetic ulcers (Heublein et al, 2015), and cutaneous wound healing (Branski et al, 2009). Microporous annealed particle (MAP) gels were created by mixing pre-gel mixture including a PEG-VS containing an RGD peptide region and matrix metalloproteinase (MMP) substrate with MMP crosslinker solution in a microfluidic channel to make gels that were annealed using FXIIIa into a final microporous scaffold (Griffin et al, 2015).…”
Section: Biomaterial-based Wound Therapiesmentioning
confidence: 99%
“…However, many mechanistic aspects of wound repair remain poorly understood, we direct the reader to other reviews for further information about detailed mechanisms of wound healing (Martin, 1997; Gurtner et al, 2008; Eming et al, 2014). In addition, we refer the reader to reviews of gene and stem cell therapies for wound healing (Branski et al, 2009; Heublein et al, 2015), role of mechanical forces in wound healing (Agha et al, 2011; Wong et al, 2011a, 2012), and immune response to biomaterial implants (Franz et al, 2011) for further information on those topics. In this review, we will focus on biomaterial- and nanoparticle (NP)-based wound therapeutics, in particular, those that have significant preclinical development or are in clinical trials/clinical use.…”
Section: Introductionmentioning
confidence: 99%
“…Diabetes mellitus (DM) is a syndrome characterized by hyperglycemia that results from absolute or relative impairment in insulin secretion and/or insulin action 1. With the development of people’s living standards and lifestyle changes, the incidence of diabetes has been rising.…”
Section: Introductionmentioning
confidence: 99%
“…BM-MSCs have demonstrated in a number of chronic wound patients (but not in all patients) to augment wound healing by reduction of inflammation, promotion of angiogenesis, acceleration of reepithelialization and inhibition of apoptosis of wound healing cells. However, it is not clear whether these effects are mediated through cellular differentiation and/or by secretion of cytokines and growth factors from the BM-MSCs [2,47,48]. BM-MSCs are relatively easy to isolate and studies have suggested minimal immunogenic response when allogeneic cells are used [48].…”
Section: Bone Marrow-derived Mesenchymal Stem Cellsmentioning
confidence: 99%
“…In the US alone, chronic wounds affect > 6 million patients annually, costing the health care system an estimated US$ 20 --25 billion [1]. On a global scale, > 380 million people suffer from diabetes, with approximately 15% of them having a diabetic foot ulcer which is responsible for approximately 80% of all lower leg amputations [2]. Despite this high incidence and heavy economic burden, current treatment of chronic wounds is far from effective and novel therapies are in urgent need.…”
Section: Introductionmentioning
confidence: 99%